Olivier Merle
Directeur Général chez Biospace Lab SA
Profil
Olivier Merle is currently the Chief Executive Officer at Biospace Lab SA. Prior to this, he worked as a Manager-Business Development at Life Technologies, Inc. and as a Principal at Transgenomic, Inc. Merle received his undergraduate degree from the École Nationale Supérieure des Mines de Saint-Étienne, his doctorate from De Montfort University, and his MBA from the University of Reims Champagne-Ardenne.
Postes actifs de Olivier Merle
| Sociétés | Poste | Début |
|---|---|---|
Biospace Lab SA
 Biospace Lab SA Electronic Equipment/InstrumentsElectronic Technology Biospace Lab SA develops and produces imaging tools. Its products include optical imaging systems and digital autoradiography solutions. The company was founded by Georges Charpak in 1989 and is headquartered in Nesles la Vallée, France. | Directeur Général | 27/04/2010 |
Anciens postes connus de Olivier Merle
| Sociétés | Poste | Fin |
|---|---|---|
Life Technologies, Inc.
 Life Technologies, Inc. BiotechnologyHealth Technology Life Technologies, Inc. provides essential technologies needed by the biotechnology and biopharmaceutical communities. The company manufactures and markets a breadth of offerings unique in the industry, used in applications of the life sciences discovery, development, and production process | Corporate Officer/Principal | - |
Transgenomic, Inc.
 Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | Corporate Officer/Principal | - |
Formation de Olivier Merle
| University of Aberdeen | Undergraduate Degree |
| De Montfort University | Doctorate Degree |
| École Nationale Supérieure des Mines de Saint-Étienne | Undergraduate Degree |
| University of Reims Champagne-Ardenne | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Biospace Lab SA
Biospace Lab SA Electronic Equipment/InstrumentsElectronic Technology Biospace Lab SA develops and produces imaging tools. Its products include optical imaging systems and digital autoradiography solutions. The company was founded by Georges Charpak in 1989 and is headquartered in Nesles la Vallée, France. | Electronic Technology |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | Health Technology |
Life Technologies, Inc.
Life Technologies, Inc. BiotechnologyHealth Technology Life Technologies, Inc. provides essential technologies needed by the biotechnology and biopharmaceutical communities. The company manufactures and markets a breadth of offerings unique in the industry, used in applications of the life sciences discovery, development, and production process | Health Technology |
